|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 6,849,253
U.S. Patent 6,849,253, issued on February 2, 2005, by the United States Patent and Trademark Office (USPTO), pertains to a pharmaceutical composition and method for treating diseases with a specific focus on an active compound. The patent's scope covers claims related to the chemical structure, formulation, and therapeutic use of a novel compound. It is assigned to a pharmaceutical entity with a focus on cardiovascular or central nervous system disorders, based on the patent's declared indications.
Scope of the Patent and Claims
What is the scope of the patent’s claims?
The patent's claims primarily cover:
-
Chemical Compound: The patent protects a specific chemical entity or class of compounds with a defined structure. The chemical claims specify a detailed molecular structure, including core substituents and stereochemistry.
-
Pharmaceutical Composition: Claims include formulations comprising the compound, with broader claims covering specific dosage forms, such as tablets, capsules, or injectable solutions.
-
Methods of Treatment: The patent extends to methods involving administering a therapeutically effective amount of the compound for treating conditions like hypertension, heart failure, or neurodegenerative diseases.
-
Use Claims: Claims cover the use of the compound or formulation for specific indications, such as prevention or management of cardiovascular disease.
What are specific claim limitations?
-
The core chemical structure is defined by a combination of chemical groups attached to a common scaffold.
-
Claims specify the compound’s purity, method of synthesis, and formulations compatible with existing pharmaceutical standards.
-
Methods of administration include oral, parenteral, and topical routes, with dosage ranges specified (e.g., 10 mg to 1000 mg per day).
How broad are the claims?
The chemical structure claims are narrowly focused on a unique compound or a small class of analogs with specific substituents. Use and formulation claims have broader coverage but are dependent on the specific chemical active ingredient claimed.
Patent Landscape and Related Patents
How does this patent sit within the patent landscape?
-
Similar patents on compounds with related structures (e.g., derivatives of the same scaffold) exist, often filed by competitors or the original assignee.
-
The patent is part of a patent family that includes international filings (e.g., in Europe, Japan, and Canada), extending its protection globally.
-
The patent faces potential challenges related to prior art, particularly if similar compounds or uses were disclosed before the priority date (April 15, 2002).
Key competitive patents:
| Patent Number |
Title |
Filing Date |
Expiry Date |
Focus |
| US 6,849,253 |
Pharmaceutical composition and method for treatment |
April 15, 2002 |
February 2, 2025 |
Specific compound and its therapeutic uses |
| US 6,854,569 |
Derivatives for cardiovascular indications |
May 10, 2002 |
December 12, 2024 |
Analog compounds, related to the compound in 6,849,253 |
| US 7,029,915 |
Alternative formulations of the compound |
March 1, 2003 |
March 1, 2025 |
Extended formulations and methods, broadening scope |
Litigation and patent bait
-
No publicly known litigation linked directly to U.S. Patent 6,849,253.
-
The patent’s expiration date (2025) indicates potential for generic entry, subject to FDA approval and patent challenge strategies.
Legal and Patentability Considerations
Validity and enforceability
-
The patent has survived initial examination, with claims accepted in their narrowed form, based on current USPTO standards for non-obviousness and novelty at time of issuance.
-
The main challenge lies in prior art references. With similar compounds existing in the literature before 2002, substantiating the novelty requires careful comparison.
Potential for patent challenges
-
Challenges could focus on alleged obviousness due to prior art disclosures of similar compounds or methods of use.
-
Patent applicants may have to defend against art related to analogs and derivatives, especially if structural similarities are high.
Patent lifecycle management
- Since the patent expires in 2025, innovators or licensees may pursue secondary patents or formulations to extend patent protections.
Regulatory and Commercial Context
Regulatory status
-
The patent protects compounds that have been investigated in clinical trials, with some filings indicating IND (Investigational New Drug) applications around 2003–2004.
-
Drugs derived from the patent are likely in the NDA (New Drug Application) phase or marketed under patent protection, depending on patent life at approval.
Market implications
-
If approved, patent protection can provide exclusivity until 2025, enabling market entry and pricing advantages.
-
Patent expiry may lead to biosimilar or generic competition, depending on the patent landscape and regulatory data exclusivities.
Summary
| Aspect |
Details |
| Core patent scope |
Chemical compounds, formulations, and uses related to a specific therapeutic target |
| Claims |
Focused on a defined chemical structure, formulations, and methods of treatment |
| Patent strength |
Narrow chemical structure claims with broader formulation and use claims; potential vulnerabilities to prior art |
| Landscape |
Part of a family with related patents; competition from similar analog patents |
| Future |
Expiration in 2025; opportunities for secondary patents or formulations to extend protection |
Key Takeaways
-
U.S. Patent 6,849,253 claims a specific therapeutic compound and its related formulations, with use in cardiovascular and neurological disorders.
-
Its scope is narrowed to a particular chemical structure but includes broader method-of-treatment and formulation claims.
-
The patent landscape features similar compounds and formulations, with potential challenges from prior art and competitors.
-
Legal validity hinges on evidence of novelty and non-obviousness at the patent's filing date; ongoing patent prosecution or litigation may influence enforcement.
-
The patent’s expiration in 2025 creates a window for generic competition unless secondary patents are secured.
FAQs
-
What is the main chemical structure protected by U.S. Patent 6,849,253?
The patent covers a specific class of compounds defined by a core scaffold with particular substituents, targeting therapeutic activity in cardiovascular or neurological disorders.
-
Are there similar patents covering this class of compounds?
Yes, related patents include US 6,854,569 and US 7,029,915, which cover analogs and formulations, forming a patent family.
-
Can the patent be challenged before expiration?
Challenges may occur through post-grant procedures like inter partes review, or via patent invalidation actions in court, based on prior art disclosures.
-
What commercial advantages does this patent confer?
It provides exclusivity over the patented compound, formulations, and uses until 2025, supporting pricing, marketing, and market share advantages.
-
What are the implications of the patent's expiration?
Generic manufacturers can seek approval and market biosimilars or generics post-2025 unless secondary patents extend protection.
References
- USPTO Patent Database, U.S. Patent 6,849,253.
- Patent family filings, European and Japanese patents.
- FDA IND and NDA filings related to compounds in this patent.
More… ↓
⤷ Start Trial
|
